Log in
NYSE:ZTS

Zoetis Stock Forecast, Price & News

$160.87
+0.40 (+0.25 %)
(As of 09/18/2020 09:31 PM ET)
Add
Compare
Today's Range
$159.12
Now: $160.87
$161.97
50-Day Range
$149.11
MA: $158.10
$165.33
52-Week Range
$90.14
Now: $160.87
$165.82
Volume2.52 million shs
Average Volume2.16 million shs
Market Capitalization$76.44 billion
P/E Ratio47.74
Dividend Yield0.50%
Beta0.76
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices and genetics. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More
Zoetis logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.2Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.26 billion
Cash Flow$4.61 per share
Book Value$5.69 per share

Profitability

Net Income$1.50 billion

Miscellaneous

Employees10,600
Market Cap$76.44 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$160.87
+0.40 (+0.25 %)
(As of 09/18/2020 09:31 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zoetis (NYSE:ZTS) Frequently Asked Questions

How has Zoetis' stock price been impacted by Coronavirus (COVID-19)?

Zoetis' stock was trading at $130.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ZTS shares have increased by 23.5% and is now trading at $160.87.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Zoetis?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 9 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zoetis
.

When is Zoetis' next earnings date?

Zoetis is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Zoetis
.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) released its quarterly earnings data on Thursday, August, 6th. The company reported $0.89 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.25. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.35 billion. Zoetis had a net margin of 25.50% and a return on equity of 63.89%. Zoetis's quarterly revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.90 earnings per share.
View Zoetis' earnings history
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Wednesday, May 20th. Investors of record on Friday, July 17th will be paid a dividend of $0.20 per share on Tuesday, September 1st. This represents a $0.80 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, July 16th.
View Zoetis' dividend history
.

How will Zoetis' stock buyback program work?

Zoetis declared that its Board of Directors has authorized a stock buyback plan on Wednesday, December 12th 2018, which allows the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 4.7% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's management believes its shares are undervalued.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY20 earnings guidance on Thursday, August, 6th. The company provided EPS guidance of $3.52-3.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.36. The company issued revenue guidance of $6.30-6.475 billion, compared to the consensus revenue estimate of $6.18 billion.

What price target have analysts set for ZTS?

18 equities research analysts have issued 12-month target prices for Zoetis' stock. Their forecasts range from $126.00 to $191.00. On average, they expect Zoetis' share price to reach $156.15 in the next twelve months. This suggests that the stock has a possible downside of 2.9%.
View analysts' price targets for Zoetis
.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Who are Zoetis' key executives?

Zoetis' management team includes the following people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.45%), Vanguard Group Inc. (8.01%), FMR LLC (2.18%), Copper Rock Capital Partners LLC (1.75%), Nuveen Asset Management LLC (1.53%) and Bank of New York Mellon Corp (0.89%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Linda Rhodes, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends for Zoetis
.

Which institutional investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., CIBC Private Wealth Group LLC, Johnson Investment Counsel Inc., Stonehage Fleming Financial Services Holdings Ltd, Point72 Asset Management L.P., Toronto Dominion Bank, and Vanguard Group Inc.. Company insiders that have sold Zoetis company stock in the last year include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Roman Trawicki, Roxanne Lagano, and Willie M Reed.
View insider buying and selling activity for Zoetis
.

Which institutional investors are buying Zoetis stock?

ZTS stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Nordea Investment Management AB, Victory Capital Management Inc., Prudential PLC, Marshall Wace LLP, Nuveen Asset Management LLC, Marshall Wace North America L.P., and Blair William & Co. IL.
View insider buying and selling activity for Zoetis
.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $160.87.

How big of a company is Zoetis?

Zoetis has a market capitalization of $76.44 billion and generates $6.26 billion in revenue each year. The company earns $1.50 billion in net income (profit) each year or $3.64 on an earnings per share basis. Zoetis employs 10,600 workers across the globe.

What is Zoetis' official website?

The official website for Zoetis is www.zoetis.com.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.